When comparing potential molecular biomarkers for Parkinson’s Disease (PD) like EGF, BRCA1, LEPR, and APP with recognized biomarkers, it’s essential to understand the context of their roles and advantages in PD. The gene discussed is EGF; the disease is Parkinson disease.